Enwei Pharmaceutical Co., Ltd. (SHE:301331)

Enwei Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	821.21	808.19	781.2	687.5	675.79	630.97
Other Revenue	3.94	3.94	3.99	4.07	3.91	3.19
Revenue	825.15	812.13	785.19	691.57	679.7	634.16
Revenue Growth (YoY)	7.46%	3.43%	13.54%	1.75%	7.18%	2.17%
Cost of Revenue	414.84	404.17	384.36	346.2	298.67	271.75
Gross Profit	410.31	407.96	400.83	345.37	381.03	362.41
Selling, General & Admin	341.98	342.52	292.84	258.17	264.71	244.19
Research & Development	8.54	9.07	16.82	7.52	4.32	4.84
Other Operating Expenses	13.15	12.56	10.89	9.89	11.64	10.35
Operating Expenses	364.51	365.98	320.45	277.06	281.34	258.66
Operating Income	45.8	41.98	80.38	68.31	99.69	103.76
Interest Expense	-3.11	-2.43	-	-	-	-0.06
Interest & Investment Income	7.86	7.59	10.3	1.99	0.52	0.33
Other Non Operating Income (Expenses)	-0.1	-0.08	-0.66	-0.27	-0.88	-2.16
EBT Excluding Unusual Items	50.46	47.07	90.03	70.03	99.33	101.87
Gain (Loss) on Sale of Investments	-	-	-	-	-0.44	-
Gain (Loss) on Sale of Assets	-0.29	-0.26	-0.04	-	-	0.01
Asset Writedown	3.13	-0.05	-	-	-0.01	-0.08
Other Unusual Items	0.89	-0.06	11.33	11.83	20.25	22.67
Pretax Income	54.18	46.68	101.31	81.86	119.13	124.47
Income Tax Expense	8.8	9.19	15	14.06	17.39	19.29
Earnings From Continuing Operations	45.38	37.5	86.31	67.8	101.73	105.18
Minority Interest in Earnings	-	-	-	-	-	-6.44
Net Income	45.38	37.5	86.31	67.8	101.73	98.74
Net Income to Common	45.38	37.5	86.31	67.8	101.73	98.74
Net Income Growth	-32.34%	-56.56%	27.30%	-33.36%	3.03%	19.55%
Shares Outstanding (Basic)	100	101	103	84	78	73
Shares Outstanding (Diluted)	100	101	103	84	78	73
Shares Change (YoY)	-1.82%	-1.82%	21.93%	8.34%	6.51%	-6.12%
EPS (Basic)	0.45	0.37	0.84	0.80	1.31	1.35
EPS (Diluted)	0.45	0.37	0.84	0.80	1.31	1.35
EPS Growth	-31.08%	-55.75%	4.40%	-38.49%	-3.27%	27.35%
Free Cash Flow	51.26	28.69	-50.04	38.8	49.36	47.36
Free Cash Flow Per Share	0.51	0.28	-0.49	0.46	0.63	0.65
Dividend Per Share	0.180	0.180	0.540	1.600	-	0.875
Dividend Growth	-66.70%	-66.70%	-66.22%	-	-	53.33%
Gross Margin	49.73%	50.23%	51.05%	49.94%	56.06%	57.15%
Operating Margin	5.55%	5.17%	10.24%	9.88%	14.67%	16.36%
Profit Margin	5.50%	4.62%	10.99%	9.80%	14.97%	15.57%
Free Cash Flow Margin	6.21%	3.53%	-6.37%	5.61%	7.26%	7.47%
EBITDA	93.2	86.85	115.13	99.22	127.79	136.54
EBITDA Margin	11.29%	10.69%	14.66%	14.35%	18.80%	21.53%
D&A For EBITDA	47.4	44.87	34.75	30.91	28.1	32.79
EBIT	45.8	41.98	80.38	68.31	99.69	103.76
EBIT Margin	5.55%	5.17%	10.24%	9.88%	14.67%	16.36%
Effective Tax Rate	16.24%	19.68%	14.81%	17.18%	14.60%	15.50%
Revenue as Reported	825.15	812.13	785.19	691.57	679.7	634.16
Advertising Expenses	-	96.67	69.92	44.22	-	30.92

Source: S&P Global Market Intelligence. Standard template. Financial Sources.